The global remote patient monitoring (RPM) market is estimated to be valued at $40 Billion in 2023, and is expected to grow ...

A Reedley girl is learning to live with her Type 1 diabetes. To help her cope with the condition, her family is trying to raise money for a service dog.

For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge. A new clinical trial at UVA is aiming to simplify diabetes management by testing an ...

For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge. A new clinical trial at UVA is aiming to ...

DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...

The global glucose monitoring devices market was valued at USD 14.1 billion in 2023 and is expected to grow to USD 15.67 ...

G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an ...

BofA Securities maintained a Buy rating on DexCom (NASDAQ:DXCM) shares, with a steady price target of $90.00. The firm's analysts suggest the current market movement presents an appealing opportunity ...

Retirement Systems of Alabama lowered its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.5% in the 4th quarter, ...

Medtronic's stock lags peers due to growth challenges in the diabetes and hypertension markets. See why we recommend a sell ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...